



Qulipta in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

NEUROLOGY · MIGRAINE PREVENTION

The clinical situation

Qulipta (atogepant) is an FDA-approved once-daily oral small-molecule CGRP receptor antagonist (gepant) indicated for the preventive treatment of episodic and chronic migraine in adults, manufactured by AbbVie. Dosing options (10 mg, 30 mg, 60 mg) are tailored by migraine pattern and tolerability. Eligibility typically anchors to documented episodic or chronic migraine with inadequate response to, or intolerance of, at least one prior standard preventive therapy. Care is led by a neurologist or headache specialist with migraine-diary tracking, triptan-use monitoring for rescue, and periodic reassessment of preventive benefit.

The pathway, 6 steps

- 1 Consultation with neurology / headache specialist.** Documented migraine history, prior preventive trials, current rescue regimen, and Qulipta clinical rationale prepared.
- 2 Baseline migraine-diary & monitoring plan.** Monthly migraine day count, triptan days, and disability scales documented.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, prior-therapy history, patient reference, and chain-of-custody plan.
- 4 US-side sourcing.** Reserve Meds coordinates with our US-licensed DSCSA-compliant specialty wholesale partner to secure Qulipta from AbbVie's authorised channel.
- 5 Shipment.** Chain-of-custody documentation travels with the product to the prescribing pharmacy.
- 6 Arrival & dispensing.** The pharmacy releases the supply with dosing instructions; the neurology team schedules follow-up assessment at 3-month intervals.

Indicative economics

Reference US cash-pay range: USD 8,500–12,000 per year (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review, keyed to the migraine prior-therapy rationale. **Logistics.** Shipment coordination to the prescribing pharmacy. **Concierge case lead.** Named point of contact managing ongoing refill logistics and follow-up reminders. **We are a**

coordinator — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist or headache specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Qulipta × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/qulipta-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team